O6-Methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma

Brain Tumor Pathology

Volumn 28, Issue 2, 2011, Pages 127-135

  Watanabe, Reiko ^a   Nakasu, Yoko ^a   Tashiro, Hiroshi ^a   Mitsuya, Koichi ^a   Ito, Ichiro ^a   Nakasu, Satoshi ^b   Nakajima, Takashi ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b Kusatsu General Hospital   (Japan)

Author keywords

Glioblastoma; Immunohistochemistry; MGMT; Temozolomide

Indexed keywords

CARBOPLATIN; ETOPOSIDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ANALYSIS; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; BRAIN TUMOR; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY; TUMOR CELL LINE;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80052723350     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-011-0022-8     Document Type: Article

References (22)

1. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in gliobalstoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
2. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003 (Pubitemid 40349502)
3. Everhard S, Tost J, Abdalaoui HE et al (2009) Identification of regions correlating MGMT promoter methylation and gene expression in bliobalstomas. Neuro Oncol 11:348-356
4. 6-methylguanine DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797 (Pubitemid 29086728)
5. Möllemann M, Wolter M, Felsberg J et al (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglioma tumors. Int J Cancer 113:379-385 (Pubitemid 40038704)
6. 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11:5167-5174 (Pubitemid 41003702)
7. 6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther 5:2531-2539 (Pubitemid 44650917)
8. Jeuken JWM, Cornelissen SJB, Vriezen M et al (2007) MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87:1055-1065 (Pubitemid 47429190)
9. Grasbon-Frodl EM, Kreth FW, Ruiter M et al (2007) Intratumoral homogeneity or MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocy-tomas and glioblastomas. Int J Cancer 121:2458-2464 (Pubitemid 350022415)
10. Capper D, Mittelbronn M, Meyermann R et al (2008) Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immu-nohistochemical approach. Acta Neuropathol 115:249-259
11. Riemenschneider M, Jeuken JWM, Wesseling P et al (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuro-pathol 120:567-584
12. Weller M, Stupp R, Reifenberger G et al (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6:39-51
13. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-1453 (Pubitemid 47339290)
14. Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280 (Pubitemid 20195640)
15. 6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol 70:333-340 (Pubitemid 40057961)
16. Gerson SL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388-2399 (Pubitemid 34441669)
17. 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17:5612-5619 (Pubitemid 27357657)
18. 6-methylguanine methyltransferase (MGMT) promoter methyl-ation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189-4199
19. 6-methyl- guanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18:520-532
20. 6-methylguanine DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neo-adjuvant temozolomide. J Clin Oncol 25:1470-1475 (Pubitemid 46733073)
21. 6-meth-ylguanine-DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro Oncol 12:28-36
22. 6-methylguanine DNA methyltrans-ferase status in glioma. Am J Surg Pathol 32:1220-1227